FDA Approves Once-Weekly Growth Hormone for Turner Syndrome
Novo Nordisk's Sogroya becomes the first once-weekly long-acting growth hormone treatment indicated for Turner syndrome in children.
Updated on Nov. 20, 2026 in Healthcare

The FDA approved Novo Nordisk's once-weekly growth hormone treatment Sogroya for children aged 2.5 years and older with growth failure associated with Turner syndrome. The approval was supported by the Phase 3 Real8 trial of 105 children.
Why it matters
The approval offers an alternative to daily injections, reducing the number of injections children with Turner syndrome receive. It expands Sogroya's existing indications, which already include growth hormone deficiency and Noonan syndrome.
In the 52-week Real8 trial of 105 children, once-weekly Sogroya produced average annual growth of 8.9 centimeters versus 9.7 centimeters for daily injections, while providing 313 injection-free days a year. The trial did not report outcomes beyond 52 weeks.
The players
Novo Nordisk
A Danish pharmaceutical company that manufactures Sogroya and other diabetes and growth hormone therapies.
The details
The FDA approval covers children aged 2.5 years and older with growth failure associated with Turner syndrome, a condition affecting around one in 2,000 newborn females. Novo Nordisk announced the approval on Friday, November 20, 2026.
Timeline
Real8 trial treatment period ran for 52 weeks, comparing once-weekly Sogroya with daily injections.
FDA approval of Sogroya was announced by Novo Nordisk on Friday, November 20, 2026.
Market Landscape
The approval extends Sogroya's established label, which already covers growth hormone deficiency and Noonan syndrome, into Turner syndrome. Novo Nordisk's stock has declined nearly 27% in 2026 while rival Eli Lilly has gained more than 25%.
Families of children with Turner syndrome may have a once-weekly option instead of daily injections, reducing the number of injections needed each year. The treatment's availability and cost coverage will depend on insurance and prescribing decisions not addressed in the extraction.
The takeaway
Once-weekly dosing may reduce the injection burden for children with Turner syndrome, though families should discuss options with a pediatric endocrinologist. Results beyond the 52-week trial period remain to be seen.
Further reading
Explore more Healthcare coverage for context on drug approvals and treatment options.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.






